Invivyd (IVVD) said Monday it has initiated an underwritten public stock offering, with all shares being sold by the company.
The underwriters have a 30-day option to buy up to 15% additional shares at the offering price, excluding discounts and commissions, the company said.
The offering's size and timing remain uncertain and depend on market and other conditions, Invivyd added.
Invivyd plans to use proceeds for VYD2311 launch readiness, research for RSV and measles programs, and studies on monoclonal antibody therapy for Long COVID, it said.
Shares of the company were down about 9.5% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments